Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.
Saved in:
| Title: | Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. |
|---|---|
| Authors: | Burton EM; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX., Tetzlaff MT; Department of Pathology, The University of California San Francisco, San Francisco, CA., Wani K; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ross MI; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY., Lazcano R; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Glitza IC; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wong MK; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Patel SP; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; University of Colorado Cancer Center, Aurora, CO., Diab A; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Gershenwald JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., McQuade JL; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Betof Warner A; Stanford University School of Medicine, Stanford University, Stanford, CA., Prieto VG; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lee JE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Goepfert RP; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., Fisher SB; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Song A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Malke J; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Simon JM; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Ariyan C; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Torres-Cabala CA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Davies MA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Lazar A; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX., Wargo JA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Tawbi HA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX., Amaria RN; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. |
| Source: | Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Sep 10; Vol. 43 (26), pp. 2856-2862. Date of Electronic Publication: 2025 Jul 10. |
| Publication Type: | Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40638872 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Burton+EM%22">Burton EM</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Milton+DR%22">Milton DR</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Tetzlaff+MT%22">Tetzlaff MT</searchLink>; Department of Pathology, The University of California San Francisco, San Francisco, CA.<br /><searchLink fieldCode="AU" term="%22Wani+K%22">Wani K</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Ross+MI%22">Ross MI</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Postow+MA%22">Postow MA</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.<br /><searchLink fieldCode="AU" term="%22Lazcano+R%22">Lazcano R</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Glitza+IC%22">Glitza IC</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Wong+MK%22">Wong MK</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Patel+SP%22">Patel SP</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.; University of Colorado Cancer Center, Aurora, CO.<br /><searchLink fieldCode="AU" term="%22Diab+A%22">Diab A</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Gershenwald+JE%22">Gershenwald JE</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22McQuade+JL%22">McQuade JL</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Betof+Warner+A%22">Betof Warner A</searchLink>; Stanford University School of Medicine, Stanford University, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Prieto+VG%22">Prieto VG</searchLink>; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Lee+JE%22">Lee JE</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Goepfert+RP%22">Goepfert RP</searchLink>; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Fisher+SB%22">Fisher SB</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Song+A%22">Song A</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Malke+J%22">Malke J</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Simon+JM%22">Simon JM</searchLink>; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Ariyan+C%22">Ariyan C</searchLink>; Department of Surgical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Torres-Cabala+CA%22">Torres-Cabala CA</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Davies+MA%22">Davies MA</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Lazar+A%22">Lazar A</searchLink>; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Wargo+JA%22">Wargo JA</searchLink>; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Tawbi+HA%22">Tawbi HA</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Amaria+RN%22">Amaria RN</searchLink>; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2025 Sep 10; Vol. 43 (26), pp. 2856-2862. <i>Date of Electronic Publication: </i>2025 Jul 10. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase II; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40638872 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1200/JCO-25-00494 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2856 Titles: – TitleFull: Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Burton EM – PersonEntity: Name: NameFull: Milton DR – PersonEntity: Name: NameFull: Tetzlaff MT – PersonEntity: Name: NameFull: Wani K – PersonEntity: Name: NameFull: Ross MI – PersonEntity: Name: NameFull: Postow MA – PersonEntity: Name: NameFull: Lazcano R – PersonEntity: Name: NameFull: Glitza IC – PersonEntity: Name: NameFull: Wong MK – PersonEntity: Name: NameFull: Patel SP – PersonEntity: Name: NameFull: Diab A – PersonEntity: Name: NameFull: Gershenwald JE – PersonEntity: Name: NameFull: McQuade JL – PersonEntity: Name: NameFull: Betof Warner A – PersonEntity: Name: NameFull: Prieto VG – PersonEntity: Name: NameFull: Lee JE – PersonEntity: Name: NameFull: Goepfert RP – PersonEntity: Name: NameFull: Fisher SB – PersonEntity: Name: NameFull: Song A – PersonEntity: Name: NameFull: Malke J – PersonEntity: Name: NameFull: Simon JM – PersonEntity: Name: NameFull: Ariyan C – PersonEntity: Name: NameFull: Torres-Cabala CA – PersonEntity: Name: NameFull: Davies MA – PersonEntity: Name: NameFull: Lazar A – PersonEntity: Name: NameFull: Wargo JA – PersonEntity: Name: NameFull: Tawbi HA – PersonEntity: Name: NameFull: Amaria RN IsPartOfRelationships: – BibEntity: Dates: – D: 10 M: 09 Text: 2025 Sep 10 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1527-7755 Numbering: – Type: volume Value: 43 – Type: issue Value: 26 Titles: – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology Type: main |
| ResultId | 1 |
